Description

This week on Pharm5:

• Ztalmy (ganaxolone) for CDKL5-CDD seizure disorder
• Opdualag (nivolumab/relatlimab-rmbw) for metastatic melanoma
• Missouri HB1677 for PBM transparency
• COVID-19 linked with increased risk and burden of T2DM
• APhA elections open until April 18th

Connect with us!

• Listen to our podcast: Pharm5
• Watch us on TikTok: @LizHearnPharmD
• Follow us on Twitter: @LizHearnPharmD

References:

1. Ztalmy. Package insert. Marinus Pharmaceuticals, Inc; 2022.
2. Opdualag. Package insert. Bristol-Myers Squibb Company; 2022.
3. Erickson K. Missouri lawmakers seek lower drug prices with plan to regulate pharmacy benefit managers. STLtoday.com. https://www.stltoday.com/news/local/govt-and-politics/missouri-lawmakers-seek-lower-drug-prices-with-plan-to-regulate-pharmacy-benefit-managers/article_c0447e7b-af83-5c53-8dac-bf3eecca0cee.html. Published March 23, 2022. Accessed March 23, 2022.
4. Becker C. State policy options and Pharmacy Benefit Managers (pbms). https://www.ncsl.org/research/health/state-policy-options-and-pharmacy-benefit-managers.aspx#/. Accessed March 23, 2022.
5. Xie Y, Al-Aly Z. Risks and burdens of incident diabetes in long covid: A cohort study. The Lancet Diabetes & Endocrinology. March 2022:1-11. doi:10.1016/s2213-8587(22)00044-4. 
6. Election Information. American Pharmacists Association. https://www.pharmacist.com/apha-elections. Accessed March 24, 2022.